April 02, 2008 - -
Exelgen, Ltd, a wholly owned subsidiary of
Commonwealth Biotechnologies, Inc. (CBI) (NASDAQ Capital Market:CBTE) and a leading provider of drug discovery chemistry services and small molecule products, announced that it has entered into two new drug discovery collaborations: one with a leading US pharmaceutical company and one with a major European pharmaceutical company. Given the proprietary nature of the collaborations both partners declined to be named.
"With our new European partner, we have entered into a broad-based collaboration to discover and develop novel small-molecule therapeutics for use in the fields of CNS; Alzheimer's disease, neuro-inflammation and type-2 diabetes...
[PDF] Commonwealth Biotechnologies' Press Release -
April 02, 2008 - -Exelgen, Ltd, a wholly owned subsidiary of Commonwealth Biotechnologies, Inc. (CBI) (NASDAQ Capital Market:CBTE) and a leading provider of drug discovery chemistry services and small molecule products, announced that it has entered into two new drug discovery collaborations: one with a leading US pharmaceutical company and one with a major European pharmaceutical company. Given the proprietary nature of the collaborations both partners declined to be named. 
"With our new European partner, we have entered into a broad-based collaboration to discover and develop novel small-molecule therapeutics for use in the fields of CNS; Alzheimer's disease, neuro-inflammation and type-2 diabetes... [PDF] Commonwealth Biotechnologies' Press Release -
